© 1997 by European Society of Cardiology
Copyright © 1997, European Society of Cardiology
Endothelin in myocardial ischaemia and reperfusion
Department of Cardiology, Karolinska Hospital, S-171 76 Stockholm, Sweden
Endothelin-1 (ET-1) is an extremely potent vasoconstrictor peptide derived from vascular endothelial cells. ET-1 can also be produced by other cell types such as smooth muscle cells and cardiomyocytes. Plasma levels of ET-1 are elevated during several different cardiovascular disorders like atherosclerosis, myocardial infarction and congestive heart failure. During and following myocardial ischaemia and reperfusion, the myocardial production and release of ET-1 is stimulated and the coronary constrictor response to ET-1 is enhanced. These findings all favour a pathophysiological role for ET-1 in the development of ischaemia/reperfusion injury. Accordingly, by using different pharmacological tools (monoclonal antibody, ET converting enzyme inhibitor or ET receptor antagonists) that block the biological actions of ET-1, myocardial ischaemia/reperfusion injury has been demonstrated to be reduced in experimental animal models, in terms of both reduction in final infarct size and improved recovery of myocardial performance and coronary flow. However, some studies have shown no cardioprotective effects of ET receptor antagonists. Possible explanations for these apparently conflicting results are differences in animal species used, route and timing of drug administration, experimental protocol and chemical nature of the antagonists. The potential mechanisms underlying the cardioprotective effects of ET antagonists are discussed and include prevention of no-reflow, inhibition of ET-induced neutrophil activation, abolishment of direct pro-ischaemic actions of ET on myocytes, and interruption of interference of ET with the renin-angiotensin system.
KEYWORDS Antagonists; Endothelin; Myocardial ischemia; Receptors; Reperfusion; Vasoconstriction
* Corresponding author. Tel. +46 8 7295876; Fax +46 8 324597.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Belaidi, M. Joyeux-Faure, C. Ribuot, S. H. Launois, P. Levy, and D. Godin-Ribuot Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1309 - 1317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Trescher, M. Bauer, W. Dietl, S. Hallstrom, N. Wick, M. Wolfsberger, R. Ullrich, G. Jurgens, E. Wolner, and B. K. Podesser Improved myocardial protection in the failing heart by selective endothelin-A receptor blockade J. Thorac. Cardiovasc. Surg., April 1, 2009; 137(4): 1005 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Deschamps, J. Zavadzkas, R. L. Murphy, C. N. Koval, J. E. McLean, L. Jeffords, S. M. Saunders, N. J. Sheats, R. E. Stroud, and F. G. Spinale Interruption of endothelin signaling modifies membrane type 1 matrix metalloproteinase activity during ischemia and reperfusion Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H875 - H883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bohm and J. Pernow The importance of endothelin-1 for vascular dysfunction in cardiovascular disease Cardiovasc Res, October 1, 2007; 76(1): 8 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Deschamps and F. G. Spinale Pathways of matrix metalloproteinase induction in heart failure: Bioactive molecules and transcriptional regulation Cardiovasc Res, February 15, 2006; 69(3): 666 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-L. Hemdahl, E. Falk, P. Thoren, and G. K. Hansson Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H872 - H877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Getting, C. Di Filippo, C. W. Lam, F. Rossi, and M. D'Amico Investigation into the Potential Anti-Inflammatory Effects of Endothelin Antagonists in a Murine Model of Experimental Monosodium Urate Peritonitis J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 90 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Liu, J.-J. Chen, P. Chan, C.-F. Cheng, and T.-H. Cheng Inhibition of Cyclic Strain-Induced Endothelin-1 Gene Expression by Resveratrol Hypertension, December 1, 2003; 42(6): 1198 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. OSTERUD and E. BJORKLID Role of Monocytes in Atherogenesis Physiol Rev, October 1, 2003; 83(4): 1069 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. O'Connor, W. A. Gattis, K. F. Adams Jr, V. Hasselblad, B. Chandler, A. Frey, I. Kobrin, M. Rainisio, M. R. Shah, J. Teerlink, et al. Tezosentan in patients with acuteheart failure and acute coronary syndromes: Results of the randomized intravenous tezosentan study (ritz-4) J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1452 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-J. Li, C.-X. Huang, C.-H. Fang, Fang Chen, Hong Jiang, Q.-Z. Tang, and G.-S. Li Circadian Variation in Ischemic Threshold in Patients with Stable Angina: Relation to Plasma Endothelin-1 Angiology, July 1, 2002; 53(4): 409 - 413. [Abstract] [PDF]
|
|
|
|
|
|
Q.-D. Wang, J. Pernow, P.-O. Sjoquist, and L. Ryden Pharmacological possibilities for protection against myocardial reperfusion injury Cardiovasc Res, July 1, 2002; 55(1): 25 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Basso, G. Thiene, M. Della Barbera, A. Angelini, M. Kirchengast, and S. Iliceto Endothelin A-receptor antagonist administration immediately after experimental myocardial infarction with reperfusion does not affect scar healing in dogs Cardiovasc Res, July 1, 2002; 55(1): 113 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. El-Solh, E. Bozkanat, J. Mador, and B. J. B. Grant Association Between Plasma Endothelin-1 Levels and Cheyne-Stokes Respiration in Patients With Congestive Heart Failure* Chest, June 1, 2002; 121(6): 1928 - 1934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pernow, A.T. Gonon, and A. Gourine The role of the endothelium for reperfusion injury Eur. Heart J. Suppl., June 1, 2001; 3(suppl_C): C22 - C27. [Abstract] [PDF]
|
|
|
|
|
|
R. Becker, B. Merkely, A. Bauer, L. Geller, L. Fazekas, K. D. Freigang, F. Voss, J. C. Senges, W. Kuebler, and W. Schoels Ventricular arrhythmias induced by endothelin-1 or by acute ischemia: a comparative analysis using three-dimensional mapping Cardiovasc Res, January 14, 2000; 45(2): 310 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Mundhenke, B Schwartzkopff, M Köstering, U Deska, R M Klein, and B E Strauer Endogenous plasma endothelin concentrations and coronary circulation in patients with mild dilated cardiomyopathy Heart, March 1, 1999; 81(3): 278 - 284. [Abstract] [Full Text]
|
|
|
|
|
|
M. Gondré and G. J. Christ Endothelin-1-Induced Alterations in Phenylephrine-Induced Contractile Responses Are Largely Additive in Physiologically Diverse Rabbit Vasculature J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 635 - 642. [Abstract] [Full Text]
|
|
|
|
|
|
P. Beaulieu and C. Lambert Peptidic regulation of heart rate and interactions with the autonomic nervous system Cardiovasc Res, March 1, 1998; 37(3): 578 - 585. [Abstract] [Full Text] [PDF]
|
|